Emcure Pharma: Motilal Oswal initiates coverage, sees 27% upside on multi-engine growth opportunity
- Posted on July 21, 2026
- By Financial Express
- 0 Views
- 1 min read
In brief
Motilal Oswal has initiated coverage of Emcure Pharma with a Buy rating and ₹2,260 price target, indicating substantial upside potential. The brokerage identifies multiple growth drivers including expansion in chronic disease treatments and international market penetration. This diversified revenue strategy positions Emcure to capitalize on emerging opportunities across therapeutic segments, supported by its established distribution network and manufacturing capabilities.
Summary auto-generated by AI from the original publisher's content. Editorial standards.
Emcure Pharma: Motilal Oswal initiates coverage, sees 27% upside on multi-engine growth opportunity
Track Emcure Pharma as Motilal Oswal starts Buy with a ₹2,260 target, citing 27% upside and multi-engine growth across chronic, global markets.
